NYSE · Healthcare
BECTON DICKINSON & CO (BDX)
As-reported financials and recent SEC filings for BECTON DICKINSON & CO, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$21.84B
Net income
$1.68B
Net margin
7.7%
Diluted EPS
$5.82
ROE
6.6%
P/E (TTM)
25.5×
Market cap
$40.30B
Debt / equity
0.7×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B |
| Gross profit | $9.93B | $9.13B | $8.17B | $8.48B | $8.63B |
| Operating income | $2.58B | $2.40B | $2.11B | $2.28B | $2.25B |
| Net income | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B |
| Diluted EPS | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
25-NSE2026-06-04
View on EDGAR →42026-06-03
View on EDGAR →42026-06-02
View on EDGAR →32026-06-02
View on EDGAR →1442026-06-01
View on EDGAR →8-K2026-05-29
View on EDGAR →42026-05-27
View on EDGAR →1442026-05-26
View on EDGAR →Go deeper on BDX
Search BECTON DICKINSON & CO’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.